94 related articles for article (PubMed ID: 16129371)
21. Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
Jernström H; Lubinski J; Lynch HT; Ghadirian P; Neuhausen S; Isaacs C; Weber BL; Horsman D; Rosen B; Foulkes WD; Friedman E; Gershoni-Baruch R; Ainsworth P; Daly M; Garber J; Olsson H; Sun P; Narod SA
J Natl Cancer Inst; 2004 Jul; 96(14):1094-8. PubMed ID: 15265971
[TBL] [Abstract][Full Text] [Related]
22. The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM; Offit K; Foulkes W; Robson ME; Wacholder S; Eng CM; Karp SE; Begg CB
Cancer Epidemiol Biomarkers Prev; 2001 May; 10(5):467-73. PubMed ID: 11352856
[TBL] [Abstract][Full Text] [Related]
23. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.
Metcalfe K; Lynch HT; Ghadirian P; Tung N; Olivotto I; Warner E; Olopade OI; Eisen A; Weber B; McLennan J; Sun P; Foulkes WD; Narod SA
J Clin Oncol; 2004 Jun; 22(12):2328-35. PubMed ID: 15197194
[TBL] [Abstract][Full Text] [Related]
24. Considerations in genetic counseling for inherited breast cancer predisposition.
Robson ME; Offit K
Semin Radiat Oncol; 2002 Oct; 12(4):362-70. PubMed ID: 12382194
[TBL] [Abstract][Full Text] [Related]
25. Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study.
Hopper JL; Southey MC; Dite GS; Jolley DJ; Giles GG; McCredie MR; Easton DF; Venter DJ
Cancer Epidemiol Biomarkers Prev; 1999 Sep; 8(9):741-7. PubMed ID: 10498392
[TBL] [Abstract][Full Text] [Related]
26. Familial breast and ovarian cancers.
Arai M; Utsunomiya J; Miki Y
Int J Clin Oncol; 2004 Aug; 9(4):270-82. PubMed ID: 15375703
[TBL] [Abstract][Full Text] [Related]
27. [Risk assessment for familial occurrence of breast cancer].
Chang-Claude J; Becher H; Hamann U; Schroeder-Kurth T
Zentralbl Gynakol; 1995; 117(8):423-34. PubMed ID: 7571905
[TBL] [Abstract][Full Text] [Related]
28. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.
Pal T; Permuth-Wey J; Betts JA; Krischer JP; Fiorica J; Arango H; LaPolla J; Hoffman M; Martino MA; Wakeley K; Wilbanks G; Nicosia S; Cantor A; Sutphen R
Cancer; 2005 Dec; 104(12):2807-16. PubMed ID: 16284991
[TBL] [Abstract][Full Text] [Related]
29. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.
Antoniou AC; Durocher F; Smith P; Simard J; Easton DF;
Breast Cancer Res; 2006; 8(1):R3. PubMed ID: 16417652
[TBL] [Abstract][Full Text] [Related]
30. Sex ratio distortion in offspring of families with BRCA1 or BRCA2 mutant alleles: an ascertainment bias phenomenon?
Balmaña J; Díez O; Campos B; Majewski M; Sanz J; Alonso C; Baiget M; Garber JE
Breast Cancer Res Treat; 2005 Aug; 92(3):273-7. PubMed ID: 16155798
[TBL] [Abstract][Full Text] [Related]
31. Factors associated with decisions about clinical BRCA1/2 testing.
Armstrong K; Calzone K; Stopfer J; Fitzgerald G; Coyne J; Weber B
Cancer Epidemiol Biomarkers Prev; 2000 Nov; 9(11):1251-4. PubMed ID: 11097234
[TBL] [Abstract][Full Text] [Related]
32. Beyond BRCA1 and BRCA2.
King-Spohn K; Pilarski R
Curr Probl Cancer; 2014; 38(6):235-48. PubMed ID: 25497410
[TBL] [Abstract][Full Text] [Related]
33. Genetic counseling program in familial breast cancer: analysis of its effectiveness, cost and cost-effectiveness ratio.
Balmaña J; Sanz J; Bonfill X; Casado A; Rué M; Gich I; Díez O; Sabaté JM; Baiget M; Alonso MC
Int J Cancer; 2004 Nov; 112(4):647-52. PubMed ID: 15382046
[TBL] [Abstract][Full Text] [Related]
34. Hereditary premenopausal breast cancer.
Strobel ES; Fritschka E
Onkologie; 2002 Feb; 25(1):24-7. PubMed ID: 11893879
[TBL] [Abstract][Full Text] [Related]
35. Treatment Decision Making and Genetic Testing for Breast Cancer: Mainstreaming Mutations.
Katz SJ; Kurian AW; Morrow M
JAMA; 2015 Sep; 314(10):997-8. PubMed ID: 26203642
[No Abstract] [Full Text] [Related]
36. Genetics and the management of women at high risk for breast cancer.
Mincey BA
Oncologist; 2003; 8(5):466-73. PubMed ID: 14530500
[TBL] [Abstract][Full Text] [Related]
37. Familial breast cancer, underlying genes, and clinical implications: a review.
Margolin S; Lindblom A
Crit Rev Oncog; 2006 Jul; 12(1-2):75-113. PubMed ID: 17078207
[TBL] [Abstract][Full Text] [Related]
38. [New genetic tests and their clinical utility for cancer screening].
Probst-Hensch NM; Brand A
Ther Umsch; 2013 Apr; 70(4):251-4; discussion 255-6. PubMed ID: 23535553
[TBL] [Abstract][Full Text] [Related]
39. Risk assessment and management of high risk familial breast cancer.
Evans DG; Lalloo F
J Med Genet; 2002 Dec; 39(12):865-71. PubMed ID: 12471197
[TBL] [Abstract][Full Text] [Related]
40. Strategies to enhance identification of hereditary breast cancer gene carriers.
Reid S; Spalluto LB; Pal T
Expert Rev Mol Diagn; 2020 Sep; 20(9):861-865. PubMed ID: 32856489
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
